<DOC>
	<DOC>NCT02836171</DOC>
	<brief_summary>he primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with itraconazole. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with itraconazole.</brief_summary>
	<brief_title>Effect of Itraconazole on the Pharmacokinetics of Apatinib</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>female of nonchildbearing potential or male; age 1845 years; body mass index 1924 kg/m2 with total body weight; clinically signiWcant medical or surgical conditions with the potential to interfere with the absorption, distribution, metabolism or excretion of the study drugs; history of alcohol abuse; smoker; electrocardiogram(ECG) abnormality; blood pressure &gt;140/90 mmHg; treatment with an investigational drug or any known CYP450 enzyme inducing/inhibiting agents or herbal supplements within 14 days prior to first dose of study medication; Subjects were to abstain from using prescription and nonprescription drugs (other than acetaminophen as deemed necessary), vitamins and dietary supplements within 14 days prior to the first dose of study medication and throughout the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>